XCSport体育

<form id='abee9'></form>

<bdo id='abee9'><sup id='abee9'><div id='abee9'><bdo id='abee9'></bdo></div></sup></bdo>

Be the most trusted biotech company

2023-01-04

Henlius Novel Anti-4-1BB×EGFR Bispecific Antibody HLX35 IND approved by NMPA
2022-12-28

Phase 3 clinical results of adalimumab biosimilar 汉达远® in psoriasis patients, published in an international journal Advances in Therapy
2022-12-21

The Phase 2 IND application of innovative PD-1 inhibitor serplulimab in combination with innovative anti-EGFR mAb HLX07 for the treatment of solid tumours was granted by the NMPA
2022-12-17

Henlius' anti-PD-1 mAb MRCT achieved 15.38 months OS in first-line treatment of SCLC, reducing the risk of death by 38% of the overall population
2022-12-09

Pre-clinical and preliminary Phase 1 clinical results of Henlius HLX07, a novel anti-EGFR mAb, published in well-known journal EXPERT OPIN BIOL TH
2022-12-07

Henlius’ Phase 3 clinical study of novel PD-1 inhibitor serplulimab for the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC) meets primary study endpoint
2022-12-03

Henlius' 4th Biologics: Bevacizumab Biosimilar 汉贝泰® Approved by National Medical Products Administration
2022-11-30

Mr. Wenjie Zhang Appointed as Chairman of Henlius, Moving Towards a More Innovative Global Biopharmaceutical Company
2022-11-24

Henlius Novel Anti PD-L1/TIGIT Bispecific Antibody Received Clinical Trial Approval in Australia